Drug
Reparixin clinical trials
Also written DF 1681Y.
Keep track of what changes. Save the reparixin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Dompé Farmaceutici S.p.A (14) · Icahn School of Medicine at Mount Sinai (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses reparixin is read from its arms, and is right about nine times in ten.
Testing it · 15
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)RecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT05835466Written as reparixin
- Add-on Reparixin in Adult Patients With ARDSCompletedPhase 2Dompé Farmaceutici S.p.ANCT05496868Written as Reparixin 600mg
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired PneumoniaTerminatedPhase 3Dompé Farmaceutici S.p.ANCT05254990Written as Reparixin
- Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver TransplantationTerminatedPhase 2Dompé Farmaceutici S.p.ANCT03031470Written as Reparixin
- Repertaxin in Prevention of Primary Graft Dysfunction After Lung TransplantationCompletedPhase 2Dompé Farmaceutici S.p.ANCT00224406Written as Repertaxin
- Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.CompletedPhase 3Dompé Farmaceutici S.p.ANCT04878055Written as Reparixin
- To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerWithdrawnPhase 2Dompé Farmaceutici S.p.ANCT05212701Written as Reparixin
- Reparixin in Prevention of Delayed Graft Function After Kidney TransplantationCompletedPhase 2Dompé Farmaceutici S.p.ANCT00248040Written as Reparixin continuous infusion
- Reparixin in COVID-19 Pneumonia - Efficacy and SafetyTerminatedPhase 2/3Dompé Farmaceutici S.p.ANCT04794803Written as Reparixin
- Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet TransplantationCompletedPhase 3Dompé Farmaceutici S.p.ANCT01817959Written as Reparixin
- Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantationCompletedPhase 2/3Dompé Farmaceutici S.p.ANCT01967888Written as Reparixin
- A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerCompletedPhase 2Dompé Farmaceutici S.p.ANCT02370238Written as Reparixin
- Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)CompletedPhase 1Dompé Farmaceutici S.p.ANCT02001974Written as Paclitaxel+Reparixin
- Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast CancerTerminatedPhase 2Dompé Farmaceutici S.p.ANCT01861054Written as Reparixin
- Reparixin in Pancreatic Islet TransplantationCompletedPhase 2Dompé Farmaceutici S.p.ANCT01220856Written as Reparixin
Codes
What other systems call reparixin · ClinicalTrials.gg INT004694
- MeSH (NLM) C490707reparixinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U604E1NB3KREPARIXINConfirmed FDA, NLM, Wikidata
- Wikidata Q27088533reparixinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66515ReparixinOne source FDA
- DrugBank DB12614One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C490707 | reparixin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U604E1NB3K | REPARIXIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088533 | reparixin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66515 | Reparixin | One source FDA |
| DrugBank | DB12614 | — | One source Wikidata |
Also registered as reparixin lysine (UNII 4RZ9P05120).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.